After 170 days of playing statue, Advertise’s Zaymer payout has SUDDENLY gone up: the financial museum piece has been lifted off its velvet cushion and sent out to earn its keep.

📼 Price tags have broken out of their mounts

👂 Slovenia’s Benaga Chaga from Shakes: $20→$40 per approved application, its first update in 258 days — the payout’s vow of silence is finally over.
💸 Russia’s LikeMoney from DALEAD climbed from 1370 to 2362 ₽ per issuance — the name finally has cash to back it up, not just a little heart under a post.
🌶 Pasodiar from Shakes in El Salvador: $6→$28 per approved application — the potency product’s most impressive erection is still its payout.
✂️ India’s VZY from Admitad cut its purchase share from 77% to 60.5% — the check’s still intact, but the affiliate slice has already been trimmed.
🩺 Estonia’s Dominero from Shakes: $20→$40 per approved application — prostatitis in the name, pep exclusively in the payout.
🫁 Bulgaria’s Benaga Chaga from Shakes slipped from $40.5 to $29 — the lung remedy’s rate has exhaled; no inhale yet.
🦵 Vezolax from Shakes: Lithuania $20→$50, Latvia and Estonia $20→$45, Portugal $20→$40 — one case of varicose veins, several very different financial strides.
🌱 Cystiolla from Aff1 added 5 targets in Bulgaria, Czechia, Spain, Italy, and Poland — a cystitis remedy with a full European tour schedule.

🏺 From the museum shelf straight to the till

Zaymer from Advertise had its payout for the “Client Quality 6” goal frozen for 170 days. Long enough for the price tag to get a “Do Not Touch” sign. Now it’s up from 2650 ₽ to 3192 ₽: even this financial still life has finally gained some value.

The set dressing is especially good: over 45 days, Advertise changed payouts for just 6 goals. In that company, any rate movement rings out like cash being counted in a library. And now we’ve got a straight +20% on a goal with an almost archival vintage. The client’s still quality level six, but the price tag is ready for its own display case.